Table 6.

Reason for choice of current therapy for recently diagnosed and established MDS patients^*

	Recently diagnosed patients, % (95% CI)(N = 549)	Established patients, % per survey (N = 4514)
Reason†		Survey 1 (n = 614)	Survey 2 (n = 664)	Survey 3 (n = 816)	Survey 4 (n = 789)	Survey 5 (n = 804)	Survey 6 (n = 827)
FAB or WHO classification	30 (26 to 33)	30	16	19	24	21	29
IPSS score	18 (15 to 22)	19	18	23	25	21	20
Hemoglobin value	14 (10 to 19)	38	26	18	‡	‡	‡
Current symptoms	30 (26 to 34)	28	25	31	28	28	32
Patient choice	30 (27 to 34)	25	28	25	23	25	25
Other	78 (74 to 81)	73	78	78	80	78	77

^*The total “n” listed at the heading of each established patients survey column includes recently diagnosed (ie, diagnosed in the previous 2 months) and established patients for whom this information was collected in that survey. Results for recently diagnosed patients were combined from across all six surveys and reported along with 95% CIs. Excludes 121 recently diagnosed patients and 594 established patients who were being monitored and were not receiving any form of therapy (ie, “watch and wait” patients). MDS = myelodysplastic syndrome; CI = confidence interval; FAB = French–American–British; WHO = World Health Organization; IPSS = International Prognostic Scoring System.

^†Reason given at the time of the survey. Categories are not mutually exclusive (patients could be on a current therapy for more than one reason).

^‡Values for hemoglobin not recorded in surveys conducted in April and September of 2006 and in January of 2007.